KNOWLEDGE, ATTITUDES AND PRACTICES OF PALESTINIAN PHARMACISTS TOWARDS PROTON PUMP INHIBITORS: A CROSS-SECTIONAL STUDY

dc.contributor.authorDana Basheer
dc.contributor.authorNiveen Rabee
dc.contributor.authorRania Ghanem
dc.date.accessioned2026-09-13T10:23:13Z
dc.date.available2026-09-13T10:23:13Z
dc.date.issued2026-05-12
dc.description.abstractAbstract Background: Proton pump inhibitors (PPIs) are widely used for managing acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. Although PPIs are effective and generally safe for short-term use, their prolonged and inappropriate use has been associated with adverse outcomes, including nutrient deficiencies, infections, and kidney disease. Objectives: This study aimed to assess the knowledge, attitudes, and practices of Palestinian community pharmacists regarding the use of PPIs. Methods: A cross-sectional study was conducted between December 2025 and March 2026 using a self-administered online questionnaire distributed among community pharmacists in Palestine. The survey consisted of four sections: sociodemographic information; pharmacists’ knowledge of PPIs (including general knowledge, side effects, and drug–drug interactions); attitudes toward PPIs; and dispensing practices. Data were analyzed using SPSS version 25. Linear regression was used to identify predictors of knowledge domains and attitudes.
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/10751
dc.language.isoen
dc.publisherDeanship of Scientific Research - Al-Quds University
dc.titleKNOWLEDGE, ATTITUDES AND PRACTICES OF PALESTINIAN PHARMACISTS TOWARDS PROTON PUMP INHIBITORS: A CROSS-SECTIONAL STUDY
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
KNOWLEDGE, ATTITUDES AND PRACTICES OF PALESTINIAN PHARMACISTS.pdf
Size:
300.42 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: